Alopecia Areata Associated with Abacavir Therapy / 감염과화학요법
Infection and Chemotherapy
; : 103-105, 2014.
Article
en En
| WPRIM
| ID: wpr-190833
Biblioteca responsable:
WPRO
ABSTRACT
Abacavir is a nucleoside reverse-transcriptase inhibitor that has been approved for use in combination with other retroviral agents in the treatment of HIV infection. Common adverse reactions include headache, fatigue, nausea, and rash. A fatal hypersensitivity reaction may occur in 5% of patients receiving abacavir; therefore, screening for HLA-B5701 should be performed before starting abacavir. Alopecia areata (AA) is infrequently reported in HIV-infected patients. Certain underlying conditions have been associated with AA, including a decreased CD4:CD8 ratio related to the progression of HIV infection, some opportunistic infections, and syphilis. Several antiretroviral drugs, such as zidovudine, indinavir, indinavir/ritonavir, lopinavir/ritonavir, and atazanavir/ritonavir have been implicated in the development of AA. At present, the occurrence of AA has not been associated with abacavir use. We cannot exclude that the use of abacavir and the development of AA could be coincidental. Nevertheless, patients given abacavir should be monitored for hair loss and the drug discontinued promptly if such signs appear.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Infecciones Oportunistas
/
Zidovudina
/
Sífilis
/
Infecciones por VIH
/
Tamizaje Masivo
/
Indinavir
/
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos
/
Alopecia
/
Alopecia Areata
/
Exantema
Tipo de estudio:
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
Infection and Chemotherapy
Año:
2014
Tipo del documento:
Article